Cancer diagnostics firm Biolidics lodges prospectus for Catalist IPO
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
MEDICAL technology firm Biolidics Limited, a cancer diagnostic solutions developer formerly known as Clearbridge Biomedics, lodged a preliminary prospectus on Friday for a planned initial public offering (IPO) on the Singapore Exchange's Catalist board.
Details of the pricing, amount to be raised, and timing of the offering have not yet been announced. UOB is the sponsor, issue manager and placement agent for the IPO.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
OCBC is said to emerge as lead bidder for HSBC Indonesia assets
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
